# **Ophthalmia Neonatorum (1 of 8)**





Not all products are available or approved for above use in all countries. Specific prescribing information may be found in the latest MIMS.

# **1** OPHTHALMIA NEONATORUM

- Conjunctivitis occuring in a newborn during the first month of life
- · Also called neonatal conjunctivitis
- Organisms causing neonatal conjunctivitis are usually acquired from the infected birth canal of the mother during vaginal delivery, though some may acquire the infection from their immediate surroundings
- One of the leading cause of blindness in infants via corneal ulceration & subsequent opacification or perforation & endophthalmitis
  - Pneumonia & otitis media are reported in some of the newborn w/ Chlamydia conjunctivitis

#### Clinical presentation

- · Eyelid & palpebral conjunctiva erythema & edema
- Purulent eye discharge

#### **Risk Factors**

- Inadequate or no prenatal care
- · Maternal infections (especially sexually transmitted diseases) before & during pregnancy
- · Exposure of the infant to infectious organisms
- · Inadequacy of ocular prophylaxis immediately after birth
- · Organisms harboring in the mother's birth canal
- · Increased shedding of organisms in the vaginal tract of the mother during the last trimester
- Ocular trauma during delivery
- Premature rupture of membranes
- Prolonged labor

# 2 DIAGNOSIS

- Laboratory diagnosis is important in identifying the causative agent & appropriate treatment Cultures
- · Indicated in all cases of suspected neonatal conjunctiviits
- Chlamydia trachomatis culture specimens should contain conjunctival cells & not exudate only
   Obtained from the everted eyelid using a dacron-tipped swab
- Neisseria gonorrhea cultures is best done using blood agar, chocolate agar &/or Thayer-Martin media
- · Viral cultures are not routinely used to establish a diagnosis

#### Histology

- Smears for cytology & special stains are recommended in cases of suspected infectious neonatal conjunctivitis
- Conjunctival scrapings for gram stain & giemsa stains should be obtained from the palpebral conjunctiva of all infants w/ neonatal conjunctivitis
- Gonococcal neonatal conjunctivitis has gram negative intracellular kidney bean-shaped diplococci in conjunctival smears
- Chlamydial neonatal conjunctivitis shows intracytoplasmic inclusion bodies in Giemsa stain
- · Herpetic conjunctivitis has eosinophilic intranuclear inclusions

#### Enzyme-Linked Immunosorbent Assay (ELISA)

 Highly sensitive & specific for diagnosing chlamydial cause of neonatal conjunctivitis w/ results obtained w/ in several hrs

#### **Direct Immunofluorescence Test**

- Gold standard for diagnosing chlamydial infections
- Shows the presence of an impressively large number of punctate, fluorescing chlamydial elementary bodies, resembling "star-spangled sky at night"

#### Microimmunofluorescence assay

· For detection of Chlamydia trachomatis IgG & IgM antibodies

# ASSESSMENT Identifying the specific cause & clinical presentation of ophthalmia neonatorum is essential in deciding the

- treatment to be given to the infant Aseptic (Non-Infectious) Usually connotes to chemical conjunctivitis Classically secondary to silver nitrate instillation for ocular infection prophylaxis Time of onset: 1-36 hrs postpartum Usually disappears w/ withdrawal of offending agent or spontaneously in 2-4 days Clinical presentation: - Mild, transient conjunctival injection w/ tearing - Lid swelling associated w/ redness of the eyes - Rarely, lacrimal stenosis Septic (Infectious) Bacterial, chlamydial or viral infection acquired during passage through an infected birth canal Due to the lack of immunity & absence of local lymphoid tissue at birth, the neonatal conjunctiva is particulalry vulnerable to infection Chlamydial neonatal conjunctivitis Genital serovars type D-K of Chlamydia trachomatis is the most frequent cause of neonatal conjunctivitis Also called inclusion conjunctivitis Time of onset: 5-14 days postpartum · Colonization of the eye w/ C. trachomatis after birth does not always result in infection Clinical presentation: - Evelid edema - Bulbar conjunctival injection - Initially the discharge is watery then becomes mucopurulent discharge - No follicles - Pseudomembrane formation - Severe cases may result in conjunctival scarring & peripheral corneal pannus w/ corneal scarring - Hemorrhagic eye discharge is a highly specific sign of neonatal chlamydial conjunctivitis · Infantile pneumonia may occur if it is left untreated - Untreated cases may persist for 3-12 mnths · Other extraocular involvement: Nasopharyngeal, rectal & vaginal colonization Gonococcal neonatal conjunctivitis Usual cause is the gram-negative diplococcus Neisseria gonorrhoeae that can penetrate an intact epithelium causing epithelial edema & corneal ulceration - More severe than chlamydial neonatal conjunctivitis as it can progress to corneal perforation, endophthalmitis & blindness if unrecognized & untreated • Incubation period: 2-5 days Time of onset: 24-48 hrs postpartum - Can present later (> 7 days) if a topical antibiotic was used - Can occur earlier in cases of premature rupture of membranes Clinical presentation: - Severe hyperacute purulent discharge Marked eyelid edema - Marked chemosis - Marked builbar conjunctival injection - Pre-auricular lymphadenopathy Other extraocular involvement: Stomatitis, arthritis, rhinitis, septicemia, meningitis & anorectal infection Other bacterial causes of neonatal conjunctivitis · Bacteria may be transmitted to the infant after birth through air w/ association w/ obstructed nasolacrimal duct
  - Gram positive organisms:
    - Staphylococcus aureus
    - Streptococcus viridians
    - Gram negative organisms:
      - Escherichia coli
    - Haemophilus sp.
      Enterobacter sp
    - Enterobacter sp

- Streptococcus pneumoniae
- Staphylococcus epidermidis
- Klebsiella pneumonia
- Proteus sp.
- Serratia marcescens
- Pseudomonas sp., rarely occur but may cause corneal perforation, blindness & death
- Time of onset: 2-5 days postpartum
- Clinical presentation:
  - Eyelid edema
  - Conjunctival injection w/ discharge
  - Chemosis
- Milder course w/o corneal & systemic involvement

# 3 ASSESSMENT (CONT'D)

#### Viral neonatal conjunctivitis

- Herpes simplex (HSV) virus type 2 can rarely cause neonatal conjunctivitis
- Time of onset: 3-15 days postpartum
- Clinical presentation:
  - Vesicular skin lesions of the lid or lid margin
  - Non-specific lid edema
  - Moderate conjunctival injection
  - Non-purulent serosanguinous discharge
  - True conjunctival membranes
  - Corneal geographic or micro-dendritic epithelial keratitis different from the typical adult herpetic dendrites

## A NON-PHARMACOLOGICAL THERAPY

#### Observation

• Chemical conjunctivitis usually resolves w/in 24-36 hrs unless there is bacterial infection complication

#### **Parent Education**

- · When appropriate, explain the natural history of the disease & the importance of prevention
- Educate parents or caregiver to wash their hands frequently to prevent transmission of neonatal conjunctivitis
- Educate pregnant women on:
  - The importance of having regular prenatal check up & prenatal care as prophylaxis
  - The importance of treating sexually transmitted infections to decrease the incidence of ophthalmia neonatorum
- Emphasize the importance of treating the mother & her sexual partner(s) as usually the causative organism is sexually transmitted

#### Normal saline irrigation

- In gonococcal conjunctivitis, normal saline irrigation helps remove the mucopurulent debris from the lids & conjunctiva
  - May be performed 4 times a day

## **B** PHARMACOLOGICAL THERAPY

#### Treatment

- · Treatment is basically based on the clinical picture & laboratory diagnosis
- Infants should be hospitalized to monitor response to treatment especially those w/ septic neonatal conjunctivitis
- Systemic treatment is usually given rather than topical drugs in order that systemic dissemination may be prevented

#### Acyclovir

- Treatment option for viral neonatal conjunctivitis
  - Recommended dosage: 30 mg/kg/day IV divided to 3 doses for at least 2 wks
- By competing w/ deoxyguanosine triphosphate for viral DNA polymerase & by incorporation into viral DNA, it inhibits viral replication

#### Aminoglycosides

- Eg Tobramycin, Gentamicin
- · Gentamicin is an alternative treatment for gonococcal neonatal conjunctivitis
  - Recommended dosage: intramuscular dose twice daily for 1 wk
- Tobramycin & Gentamicin may be used as treatment for gram-negative bacteria causing neonatal conjunctivitis (except *N. gonorrhea*)
  - Recommended dosage: Oint or drops 4 times a day

#### Azithromycin

- Alternative treatment for patients w/ chlamydial conjunctivitis intolerant to Erythromycin
  - Recommended dosage: 20 mg/kg/day orally for 3 days
  - Studies proving the efficacy of Azithromycin for chlamydial conjunctivitis are limited

Not all products are available or approved for above use in all countries. Specific prescribing information may be found in the latest MIMS.

## B PHARMACOLOGICAL THERAPY (CONT'D)

#### Cefotaxime

Treatment option for neonates w/ gonococcal conjunctivitis & hyperbilirubinemia
 Recommended dosage: 100 mg/kg IV or IM

#### Ceftriaxone

- Drug of choice for gonococcal neonatal conjunctivitis
  - Recommended dosage: 25-50 mg/kg IV or IM as a single dose, not to exceed 125 mg
  - Topical antibiotic therapy alone is inadequate & is unnecessary when systemic treatment is administered
- · Inhibits bacterial growth by binding to one or more of the penicillin-binding proteins
- Use w/ caution in infants who is born prematurely & w/ hyperbilirubinemia

#### Erythromycin

- · Drug of choice for chlamydial neonatal conjunctivitis
  - Recommended dosage: 50 mg/kg/day orally in 4 divided doses for 14 days
  - Topical antibiotic therapy alone is inadequate & is unnecessary when systemic treatment is administered
  - Advantages of oral Erythromycin include: Eradication of the nasopharyngeal carriers, treatment of associated pneumonitis & also being more effective than topical in preventing relapse of conjunctivitis
  - A second course of treatment may be required thus monitoring the response to treatment is necessary
- Also used for treatment of other gram-positive bacteria causing neonatal conjunctivitis
   Dosage: 0.5% ointment 4 times a day
- May cause infantile hypertrophic pyloric stenosis
- Signs & symptoms of this disease (eg intestinal obstruction) should be monitored

#### Penicillin G

- · Alternative treatment for gonococcal neonatal conjunctivitis
- Recommended dosage: 100,000 units/kg/day IV in 4 divided doses for 1 wk
- Inhibits bacterial growth by binding to one or more of the penicillin-binding proteins

#### Trifluridine (Trifluorothymidine)

- Treatment option for viral neonatal conjunctivitis
  - Recommended dosage: 1% ophthalmic drops every 2 hrs for 7 days
- · Inhibits viral replication by incorporating into the viral DNA in place of thymidine

#### Vidarabine

· Adjunct therapy to Acyclovir for the treatment of viral neonatal conjunctivitis

#### Prophylaxis

• Easy to administer, safe & inexpensive in preventing sight-threatening gonococcal neonatal conjunctivitis

#### Erythromycin

- · Drug of choice for neonatal conjunctivitis prophylaxis
  - Recommended dosage: 0.5% Erythromycin oint 1 cm ribbon in each eye as single dose applied as soon as possible after birth
  - Preferred prophylaxis than silver nitrate due to less incidence of chemical conjunctivitis
- Effective prophylaxis for gonococcal neonatal conjunctivitis but not in chlamydial neonatal conjunctivitis
- · Inhibits bacterial growth by inhibiting bacterial RNA-dependent protein synthesis

#### Povidone-iodine

- · Alternative prophylaxis for chlamydial neonatal conjunctivitis
- 2.5% ophthalmic soln in each eye applied as soon as possible after birth
- Studies have shown that it has superior bactericidal effects & also active against viruses but further studies are
  recommended

### Silver nitrate

- More effective as a prophylaxis for *N. gonorrhea* than Erythromycin & should be used in areas where that organism is prevalent
- Not effective prophylaxis for C. trachomatis
- Usage as prophylaxis is discouraged as it can cause chemical neonatal conjunctivitis

#### Tetracycline

- · Alternative prophylaxis for chlamydial neonatal conjunctivitis
  - Recommended dosage: 1% Tetracycline oint 1 cm ribbon in each eye as single dose applied as soon as possible after birth
- Inhibits bacterial protein synthesis by binding to the 30S & possible the 50S ribosomal subunits of susceptible bacteria preventing additions of amino acids to the growing peptide chain

Not all products are available or approved for above use in all countries. Specific prescribing information may be found in the latest MIMS.

# **Dosage Guidelines**

ANTIVIRAL					
Drug	Dosage	Remarks			
Aciclovir (Acyclovir)	10 mg/kg IV 8 hrly x 10 days	<ul> <li>Adverse Reactions</li> <li>GI effects (N/V, diarrhea, inc liver enzymes); Local effects (injection site pain, inflammation, phlebitis, extravasation); CNS effects (seizures, coma, tremors); Other effects (hypersensitivity reactions, hematological changes)</li> <li>Special Instructions</li> <li>Use w/ caution in patients w/ renal impairment, neurological/ hepatic abnormalities, electrolyte imbalance</li> </ul>			

CEPHALOSPORINS				
Drug	Dosage	Remarks		
Cefotaxime	50-100 mg/kg/day IV/IM 12 hrly	<ul> <li>Adverse Reactions</li> <li>GI effects (N/V, diarrhea, hepatitis); Hematologic effects (leucopenia, eosinophilia, thrombocytopenia); Other effects (inj site irritation, hypersensitivity reactions, urticaria, exanthema)</li> <li>Special Instructions</li> <li>Use w/ caution in patients w/ pseudomembranous colitis, renal insufficiency</li> </ul>		
Ceftriaxone	20-80 mg/kg/day IV/IM 24 hrly	<ul> <li>Adverse Reactions</li> <li>GI effects (diarrhea, inc liver enzymes, pseudomembranous colitis); Hematologic effects (leucopenia, neutropenia, blood dyscrasias); Other effects (hypersensitivity reactions, pruritus, rash, fever)</li> <li>Special Instructions</li> <li>Use w/ caution in patients w/ renal impairment, superinfection</li> </ul>		

EYE ANTI-INFECTIVES & ANTISEPTICS				
Drug	Available Strength	Dosage	Remarks	
Chloramphenicol	1% ophth oint	Apply 3 hrly for the first 48 hrs postpartum	<ul> <li>Adverse Reactions</li> <li>Hematological effect (bone marrow hypoplasia including aplastic anemia); Other effects (allergic reactions, superinfection)</li> <li>Special Instructions</li> <li>Avoid prolonged use as it can cause overgrowth of nonsusceptible organisms</li> </ul>	
Erythromycin	0.5 % ophth oint	Apply 1-cm ribbon into each conjunctival sac once	<ul> <li>Adverse Reactions</li> <li>Ocular effects (minor irritation, redness); Other effects (hypersensitivity reactions)</li> <li>Special Instructions</li> <li>After application, massage eyelid to spread the oint</li> <li>A minute after application, wipe excess oint using a sterile cotton</li> </ul>	

All dosage recommendations are for children w/ normal renal & hepatic function unless otherwise stated.

Not all products are available or approved for above use in all countries.

Products listed above may not be mentioned in the disease management chart but have been placed here based on indications listed in regional manufacturers' product information.

Specific prescribing information may be found in the latest MIMS.

# **Dosage Guidelines**

EYE ANTI-INFECTIVES & ANTISEPTICS (CONT'D)				
Drug	Available Strength	Dosage	Remarks	
Gentamicin <sup>1</sup>	0.3% ophth drops	Apply 1-2 drops 4-6 hrly	<ul> <li>Adverse Reactions</li> <li>Ocular effects (bacterial/fungal corneal ulcer, burning, irritation, nonpecific conjunctivitis, conjunctival epithelial defects, conjunctival hyperemia); Other effects (allergic reactions, thrombocytopenic purpura)</li> <li>Special Instructions</li> <li>Avoid prolonged use as it can cause overgrowth of nonsusceptible organisms</li> </ul>	
Trifluridine (Trifluorothymidine)	1% ophth	Instill 1 drop 2 hrly	<ul> <li>Adverse Reactions</li> <li>Ocular effects (palpebral edema, superficial punctate keratopathy, stromal edema, keratitis sicca, increased intraocular pressure)</li> <li>Special Instructions</li> <li>Avoid prolonged use as it can cause overgrowth of nonsusceptible organisms</li> </ul>	
Vidarabine (Vidarabine monohydrate)	3% ophth oint	Apply 0.5 inch ribbon into the lower conjunctival sac of each eye 3 hourly	<ul> <li>Adverse Reactions</li> <li>Ocular effects (lacrimation, conjunctival inj, superficial punctate keratitis, punctal occlusion, uveitis, corneal vascularization)</li> <li>Special Instructions</li> <li>Avoid use w/ corticosteroid</li> </ul>	

<sup>1</sup>Gentamicin in combination w/ corticosteroids is available. Please see the latest MIMS for specific formulations.

MACROLIDES			
Drug	Dosage	Remarks	
Azithromycin	10 mg/kg PO 24 hrly x 3 days	<ul> <li>Adverse Reactions</li> <li>Cardiac effects (arrhythmia, QT prolongation, Torsades de pointes); GI effects (vomiting, diarrhea, constipation, pseudomembranous colitis, tongue discoloration, cholestatic jaundice); Renal effects (acute renal failure, interstitial nephritis); CNS effects (convulsions, hyperactivity); Other effects (hypersensitivity reactions, thrombocytopenia)</li> <li>Special Instructions</li> <li>Use w/ caution in patients w/ cardiac arrhythmia, congenital OT prolongation, electrolyte disturbance, cardiac insufficiency</li> </ul>	
Erythromycin	30-50 mg/kg/day PO x 14 days	<ul> <li>Adverse Reactions</li> <li>Cardiac effects (arrhythmia, QT prolongation, Torsades de pointes); GI effects (vomiting, diarrhea, constipation, pseudomembranous colitis, tongue discoloration, cholestatic jaundice); Renal effects (acute renal failure, interstitial nephritis); CNS effects (convulsions, hyperactivity); Other effects (hypersensitivity reactions, thrombocytopenia)</li> <li>Special Instructions</li> <li>Use w/ caution in patients w/ cardiac arrhythmia, congenital QT prolongation, electrolyte disturbance, cardiac insufficiency</li> </ul>	

All dosage recommendations are for children w/ normal renal & hepatic function unless otherwise stated. Not all products are available or approved for above use in all countries. Products listed above may not be mentioned in the disease management chart but have been

placed here based on indications listed in regional manufacturers' product information.

 $Specific\ prescribing\ information\ may\ be\ found\ in\ the\ latest\ MIMS.$ 

Please see the end of this section for the reference list.